Katherine G. Moss
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Angiogenesis and VEGF in Cancer, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Microtubule and mitosis dynamics
Most-Cited Works
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.(2003)
- → GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition(2011)594 cited
- → Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity(2013)426 cited
- → Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors(2013)254 cited
- → Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions(2013)213 cited
- → Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)(2011)191 cited
- → SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice(2002)133 cited
- → GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models(2009)110 cited
- → Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248(2006)109 cited
- → Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo(1996)102 cited